CTIX Recent activities 08/17/2014 04:27:03 $CTIX
CTIX Latest DD (Updated)
"* Kevetrin Phase 1--Cohort 8 in progress @ 215mg/m2--No MTD yet established--http://cellceutix.com/cellceutix-clinical-trial-of-anti-cancer-drug-kevetrin-entering-eighth-cohort/#sthash.6pctRV6R.dpbs
* K in combination against renal completed most if not all preclinical work.
* K in combination against leukemia (AML) already [completed] preclinical work at UofB and a Phase 1b/2 Clinical Trial is poised to start once MTD is established in K/P1
* K against Retinoblastoma announced in March 2013 will commence after MTD is established in P1
* Prurisol bridge study complete--Awaiting final report before submission to FDA for P2 trial--Anticipated start date 1Q/15--http://cellceutix.com/cellceutix-anti-psoriasis-drug-prurisol-meets-primary-endpoint-of-clinical-trial/#sthash.fYZzgvRO.dpbs
* B against ABSSSI near 100% enrollment and treated NO AE's--Expected completion within a couple of weeks
* B OM Preparing to submit to FDA for approval of P2 trial--http://cellceutix.com/cellceutix-prepares-for-phase-2-clinical-trial-of-brilacidin-om-for-oral-mucositis/#sthash.SpoCUTpB.dpbs--
* B ocular formulation studies underway at Dr Reddy's and should complete within the next few to 6 months.
* B otic also in formulation studies at Dr Reddy's
* B DFI just announced high efficacy and should begin final preclinical work ahead of clinical testing. "
*B NY/ NJ universities material transfer agreement defensive mimetics
*Cellceutix in June, 2014, entered into a research agreement with a renowned non-profit research institution for studies of anti-fungal compounds in Cellceutix’s portfolio. The research is to be funded by a $1.5 million grant from the National Institute of Health, Small Business Innovation Research (SBIR) to the non-profit institution.
I figure this is a good time to rehash this as there are new eyes abound lately.
Thanks to Alex for putting most of this together.
Thanks for the list Farrell! My favorite is #6, especially this statement:
*Stabilization was achieved at low doses in terminal patients with relapsed tumors that were resistant to current chemotherapies
Since the trial was in the 5th cohort at that time, the "low doses" had to be 75 mg/m2 or less. Now cohort 8 is almost 3x the dosage. This is the reason why I am really looking forward to this year's R&R. Only three more weeks.
vip,
that also makes this interesting to watch play out. Will it form a handle or just breakout. Timing of news could play a big part in that. The size of friday's move and closing a fair distance above the upper bb could favor the forming of a handle. Especially, since historically CTIX gets back inside the bb's very quickly.
Would be a nice spot for a bull flag too.
Thanks for the discussion vip and ee. Have a great finish to your weekend and Trade Green.
Cup and handle, waiting for the cup to form completely at 1.90 then a short handle and the way we go.
http://stockcharts.com/school/doku.php?st=cup...ntinuation
Quote:
BigKahuna Friday, 10/05/12 06:53:29 PM
Re: None
CTIX Latest DD (Updated)
"* Kevetrin Phase 1--Cohort 8 in progress @ 215mg/m2--No MTD yet established--http://cellceutix.com/cellceutix-clinical-trial-of-anti-cancer-drug-kevetrin-entering-eighth-cohort/#sthash.6pctRV6R.dpbs
* K in combination against renal completed most if not all preclinical work.
* K in combination against leukemia (AML) already [completed] preclinical work at UofB and a Phase 1b/2 Clinical Trial is poised to start once MTD is established in K/P1
* K against Retinoblastoma announced in March 2013 will commence after MTD is established in P1
* Prurisol bridge study complete--Awaiting final report before submission to FDA for P2 trial--Anticipated start date 1Q/15--http://cellceutix.com/cellceutix-anti-psoriasis-drug-prurisol-meets-primary-endpoint-of-clinical-trial/#sthash.fYZzgvRO.dpbs
* B against ABSSSI near 100% enrollment and treated NO AE's--Expected completion within a couple of weeks
* B OM Preparing to submit to FDA for approval of P2 trial--http://cellceutix.com/cellceutix-prepares-for-phase-2-clinical-trial-of-brilacidin-om-for-oral-mucositis/#sthash.SpoCUTpB.dpbs--
* B ocular formulation studies underway at Dr Reddy's and should complete within the next few to 6 months.
* B otic also in formulation studies at Dr Reddy's
* B DFI just announced high efficacy and should begin final preclinical work ahead of clinical testing. "
*B NY/ NJ universities material transfer agreement defensive mimetics
*Cellceutix in June, 2014, entered into a research agreement with a renowned non-profit research institution for studies of anti-fungal compounds in Cellceutix’s portfolio. The research is to be funded by a $1.5 million grant from the National Institute of Health, Small Business Innovation Research (SBIR) to the non-profit institution.
I figure this is a good time to rehash this as there are new eyes abound lately.
Thanks to Alex for putting most of this together.
Thanks for the list Farrell! My favorite is #6, especially this statement:
*Stabilization was achieved at low doses in terminal patients with relapsed tumors that were resistant to current chemotherapies
Since the trial was in the 5th cohort at that time, the "low doses" had to be 75 mg/m2 or less. Now cohort 8 is almost 3x the dosage. This is the reason why I am really looking forward to this year's R&R. Only three more weeks.
vip,
that also makes this interesting to watch play out. Will it form a handle or just breakout. Timing of news could play a big part in that. The size of friday's move and closing a fair distance above the upper bb could favor the forming of a handle. Especially, since historically CTIX gets back inside the bb's very quickly.
Would be a nice spot for a bull flag too.
Thanks for the discussion vip and ee. Have a great finish to your weekend and Trade Green.
Cup and handle, waiting for the cup to form completely at 1.90 then a short handle and the way we go.
http://stockcharts.com/school/doku.php?st=cup...ntinuation
Quote:
BigKahuna Friday, 10/05/12 06:53:29 PM
Re: None
